These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 36358716)

  • 41. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
    Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
    Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
    Front Oncol; 2022; 12():978069. PubMed ID: 36330494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors.
    Crespin A; Le Bescop C; de Gunzburg J; Vitry F; Zalcman G; Cervesi J; Bandinelli PA
    Front Oncol; 2023; 13():1075593. PubMed ID: 36937417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Li S; Wang T; Tong G; Li X; You D; Cong M
    Front Oncol; 2021; 11():726257. PubMed ID: 34513704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.
    Na N; Yao J; Cheng C; Huang Z; Hong L; Li H; Qiu J
    Oncotarget; 2016 Jul; 7(28):44039-44046. PubMed ID: 27270655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy.
    Guven DC; Sahin TK; Erul E; Cakir IY; Ucgul E; Yildirim HC; Aktepe OH; Erman M; Kilickap S; Aksoy S; Yalcin S
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
    Öjlert ÅK; Nebdal D; Lund-Iversen M; Åstrøm Ellefsen R; Brustugun OT; Gran JM; Halvorsen AR; Helland Å
    Acta Oncol; 2021 Feb; 60(2):149-156. PubMed ID: 33356733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Liu B; Kotenko S; Li W
    Medicine (Baltimore); 2022 Aug; 101(32):e29536. PubMed ID: 35960066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
    Vartolomei MD; Porav-Hodade D; Ferro M; Mathieu R; Abufaraj M; Foerster B; Kimura S; Shariat SF
    Urol Oncol; 2018 Sep; 36(9):389-399. PubMed ID: 29884342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Wang H; Zhou F; Qiao M; Li X; Zhao C; Cheng L; Chen X; Zhou C
    Front Oncol; 2021; 11():671874. PubMed ID: 34367957
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.
    Mei Z; Shi L; Wang B; Yang J; Xiao Z; Du P; Wang Q; Yang W
    Cancer Treat Rev; 2017 Jul; 58():1-13. PubMed ID: 28602879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical predictors of response to single‑agent immune checkpoint inhibitors in chemotherapy‑pretreated non‑small cell lung cancer.
    Musaelyan AA; Moiseyenko FV; Emileva TE; Oganesyan AP; Oganyan KA; Urtenova MA; Odintsova SV; Chistyakov IV; Degtyarev AM; Akopov AL; Imyanitov EN; Orlov SV
    Mol Clin Oncol; 2024 Apr; 20(4):32. PubMed ID: 38476335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma.
    Waninger JJ; Fecher LA; Lao C; Yentz S; Green MD; Demirci H
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis.
    Takenaka Y; Oya R; Takemoto N; Inohara H
    Head Neck; 2022 May; 44(5):1237-1245. PubMed ID: 35146824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma.
    Wu X; Han R; Zhong Y; Weng N; Zhang A
    Cancer Cell Int; 2021 Jul; 21(1):356. PubMed ID: 34233686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neutrophil-to-lymphocyte ratio is an independent predictor for survival outcomes in cervical cancer: a systematic review and meta-analysis.
    Zou P; Yang E; Li Z
    Sci Rep; 2020 Dec; 10(1):21917. PubMed ID: 33318608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study.
    Lee PY; Oen KQX; Lim GRS; Hartono JL; Muthiah M; Huang DQ; Teo FSW; Li AY; Mak A; Chandran NS; Tan CL; Yang P; Tai ES; Ng KWP; Vijayan J; Chan YC; Tan LL; Lee MB; Chua HR; Hong WZ; Yap ES; Lim DK; Yuen YS; Chan YH; Aminkeng F; Wong ASC; Huang Y; Tay SH
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.